BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38049338)

  • 21. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG; Agrawal M; Corbacioglu A; Weber D; Kapp-Schwoerer S; Gaidzik VI; Jahn N; Schroeder T; Wattad M; Lübbert M; Koller E; Kindler T; Götze K; Ringhoffer M; Westermann J; Fiedler W; Horst HA; Greil R; Schroers R; Mayer K; Heinicke T; Krauter J; Schlenk RF; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Döhner K
    Blood; 2019 Nov; 134(19):1608-1618. PubMed ID: 31554635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
    Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia.
    Macke EL; Meyer RG; Hoppman NL; Ketterling RP; Greipp PT; Xu X; Baughn LB; Shafer DA; He RR; Peterson JF
    Lab Med; 2022 Jul; 53(4):e87-e90. PubMed ID: 34791328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
    Agrawal M; Schwarz P; Giaimo BD; Bedzhov I; Corbacioglu A; Weber D; Gaidzik VI; Jahn N; Rücker FG; Schroeder T; Kindler T; Wattad M; Götze K; Lübbert M; Salwender H; Ringhoffer M; Lange E; Koller E; Thol F; Heuser M; Ganser A; Bullinger L; Paschka P; Döhner H; Geiger H; Borggrefe T; Döhner K; Oswald F
    Leukemia; 2020 Feb; 34(2):630-634. PubMed ID: 31462736
    [No Abstract]   [Full Text] [Related]  

  • 25. Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Zhang S; Zhou W; Li Y; Yu S; Xue M; Qiao Y; Jian J; Liu B; Wang D
    Leuk Lymphoma; 2019 May; 60(5):1316-1319. PubMed ID: 30328750
    [No Abstract]   [Full Text] [Related]  

  • 26. [Acute myeloid leukemia (aml) subtype M2 with variation of the t (8;21)translocation and AML1/ETO expression].
    Llimpe Y; Monteza R; Ticlahuanca J; Rubio P; Ortíz C; Arias A
    Rev Peru Med Exp Salud Publica; 2013 Mar; 30(1):145-6. PubMed ID: 23612831
    [No Abstract]   [Full Text] [Related]  

  • 27. Trinh BQ, Ummarino S, Zhang Y, et al. Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021;138(15):1331-1344.
    Blood; 2023 May; 141(20):2542. PubMed ID: 37200056
    [No Abstract]   [Full Text] [Related]  

  • 28. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
    Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N
    Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
    Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
    Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
    [No Abstract]   [Full Text] [Related]  

  • 30. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
    XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
    Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
    Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
    Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells.
    Yan JS; Li YD; Liu SH; Yin QQ; Liu XY; Xia L; Lu Y
    Leuk Lymphoma; 2017 Aug; 58(8):1985-1988. PubMed ID: 28092997
    [No Abstract]   [Full Text] [Related]  

  • 33. [Co-existence of AML1-ETO and BCR-ABL1 fusion genes in acute myeloid leukemia: a case report].
    Yao YQ; Jia X; Liu H; Lu QS; Xiong WJ; Zhang Y; Liu QF; Shi PC
    Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):203-206. PubMed ID: 38326048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1.
    Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Sasaki K; Tsujimoto S; Miyake M; Uchiyama Y; Ikeda J; Yoshitomi M; Shimosato Y; Tokumasu M; Matsuo H; Yoshida K; Ohki K; Kaburagi T; Yamato G; Hara Y; Takeuchi M; Kinoshita A; Tomizawa D; Taga T; Adachi S; Tawa A; Horibe K; Hayashi Y; Matsumoto N; Ito S; Shiba N
    Br J Haematol; 2021 Jul; 194(2):414-422. PubMed ID: 34120331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.
    Al-Harbi S; Aljurf M; Mohty M; Almohareb F; Ahmed SOA
    Blood Adv; 2020 Jan; 4(1):229-238. PubMed ID: 31935293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia.
    Grinev VV; Barneh F; Ilyushonak IM; Nakjang S; Smink J; van Oort A; Clough R; Seyani M; McNeill H; Reza M; Martinez-Soria N; Assi SA; Ramanouskaya TV; Bonifer C; Heidenreich O
    Nat Commun; 2021 Jan; 12(1):520. PubMed ID: 33483506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1.
    Kim M; Kim J; Kim JR; Han E; Park J; Lim J; Kim Y; Han K; Kim HJ; Min WS; Cho B
    Mol Biol Rep; 2015 Feb; 42(2):451-6. PubMed ID: 25287662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.
    Peterson LF; Boyapati A; Ahn EY; Biggs JR; Okumura AJ; Lo MC; Yan M; Zhang DE
    Blood; 2007 Aug; 110(3):799-805. PubMed ID: 17412887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.